Currently we are seeing a huge shift in the valuations in cannabis stocks, the market doesn’t care anymore for the typical low-cost LP story. Companies need to prove their valuations with real revenue, sales channels, or valuable intellectual property. Which is hard to accomplish because even post legalization, the Canadian government is still unprepared for the industry and is still adjusting regulation guidelines to date.
We believe investors aren’t seeing the full picture/value in FSD Pharma as we are constructing our state-of-the-art facility and being pre-revenue. The investors that will see the best ROI on FSD Pharma are presently invested in this early stage. The Company has a lot ahead for Q1 2019, set to complete our first HUGE development of 220,000 square feet, sales license pending, actively pursuing a Nasdaq listing, partnership IPOs, and continuing to establish sales channels. Apart from market valuations, macro market conditions, we remain confident with our financial stance and fundamentals.
The next major market wave in the sector and for FSD Pharma we believe will be in cannabis biotech with R&D, there are over 200 compounds in the cannabis plant and science has yet to discover all combinations and possible treatments the plant can disrupt. “There are currently more than two dozen countries worldwide where medical cannabis is legal, and FSD intends to be a supplier to these markets” - Dr. Raza Bokhari.
Positive Earnings per share in Q3 of $0.003
Strong cash position, exiting September 30, 21018 with $33.8 million and no debt.
What are your thoughts on just the above as it relates to your current market cap (and therefore share price) … and why do you believe investors are not seeing this specific tree in the forest?
What is the importance of your December 6th news that FSD Pharma entering a Collaboration and License Agreement with World Class Extractions? What is the differentiator or disruptor here?
152